<DOC>
	<DOCNO>NCT02197143</DOCNO>
	<brief_summary>- Currently , Proton Pump Inhibitors H2Receptor Blockers widely use emergency physician Turkey treatment patient dyspepsia . - The objective study ass whether intravenous esomeprazol superior dyspeptic pain reduction compare ranitidine hydrotalcid emergency department ( ED ) adults - The investigator second aim compare recurrent dyspeptic pain within 24 hour discharge cost treatment treatment dyspepsia .</brief_summary>
	<brief_title>A Comparison Efficacy Intravenous Esomeprazole Ranitidine Treatment Dyspeptic Pain</brief_title>
	<detailed_description>- placebo randomize double blind clinical trial compare efficacy three drug clinical setting . - A randomized clinical trial conduct ED Pamukkale University Medical Faculty Hospital - Study personnel ( emergency physicians nurse ) train study . - When intravenous drug ( esomeprazol , ranitidine plasebo ) recommend , eligibility checklist complete attend physician . - If exclusion criterion , write informed consent obtain baseline information , include initial dispeptic pain severity rating VAS record . - The need identification enrollment participant staff conflict work pressure result recruitment convenience sample patient . - All patient eligible study randomize one three group : - First Group : 40 mg Esomeprozol 5 cc syringe 150 ml normal saline give slow intravenous infusion 15 minute p.o . 10ml Hidrotalcid - Second Group : 50mg Ranitidin 5 cc syringe 150 ml normal saline give slow intravenous infusion 15 minute p.o . 10ml Hidrotalcid - Third Group : 150 ml normal saline give slow intravenous infusion 15 minute p.o . 10ml Hidrotalcid - Drug pack prepare 5 ml syrinx number independent nurse , involve study . - Drug pack prepare accord computer-generated random number sequence assign treatment allocation - The allocation list keep emergency nurse . Patients receive esomeprazol , ranitidin placebo medication scheme accord random allocation . - After enrollment record baseline information , next numbered study drug pack obtain , administer infusion 15 minute . - Randomization achieve use computer software generate random number . During intervention , participant monitor oxygen saturation ( SpO2 ) monitor , automatic sphygmomanometer ( blood pressure ) , rhythm monitor ( heart rate rhythm ) - One researcher blind patient allocation observe whole procedure record dyspeptic pain score . - Patients group receive three type medication similar manner ( example , 150 ml normal saline give slow intravenous infusion 15 minute ) , thus ensure double blinding . - Dyspeptic pain score record 0 , 15 , 30 , 45 60 min VAS 1 10 - Rescue medication [ hidrotalcid 10ml ( Talcid , Bayer , Istanbul , Turkey ) ] give intravenously patient dyspeptic pain VAS score â‰¥ 5 thirty minute study drug administration . - All medication require study also record . - During study , pulse rate , systolic blood pressure , diastolic blood pressure , respiration rate oxygen saturation ( SpO2 ) record baseline ( 0 min ) , 15 , 30 , 60 min .</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<criteria>patient eligible inclusion age 18 year old , 60 year old , dyspspsia [ VAS ( visual analog scale ) score &gt; 5 ] ED episode care attend physician recommend medication . pretreatment 100mm linear visual analog scale ( VAS ) pain score less 50 mm ; know case malignancy terminal illness ; know case major medical problem ( eg , evidence active structural functional abnormality heart , chronic renal failure ) allergy previous adverse reaction study drug study received agent inhibit secretion acid ( PPIs histamine2 receptor antagonist ) , nonsteroidal antiinflammatory drug , consume alcohol within 4 hour ED visit diarrhea 2 time within past 24 hour ; suspect ED diagnosis ( eg , gut obstruction , biliary colic , pancreatitis , hepatitis , localize hepatobiliary infection ) ; pregnant breastfeeding ; inability comprehend VAS evaluation . patient refuse participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>esomeprazole</keyword>
	<keyword>ranitidine</keyword>
	<keyword>hydrotalcid</keyword>
	<keyword>treatment dyspepsia</keyword>
	<keyword>emergancy medicine</keyword>
</DOC>